Hengrui Pharmaceutical announced on the evening of July 8. Recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-2173 injections and will conduct clinical trials in the near future. SHR-2173 injection is a therapeutic biological product independently developed by the company. It can exert anti-inflammatory and immune-suppressing biological effects by targeting abnormally activated immune cells. It is expected to reduce autoantibody levels, improve disease activity in patients with primary membranous nephropathy, and bring new treatment options to patients. Currently, there are no similar drugs on the market or in the clinical development stage at home or abroad. The company announced on the same day that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-9821 inhalation powder and will conduct clinical trials in the near future. HRS-9821 is a small molecule PDE3/PDE4 inhibitor that can effectively inhibit respiratory inflammation and bronchodilation. It is clinically intended for maintenance treatment of COPD.

Zhitongcaijing · 07/08/2025 09:17
Hengrui Pharmaceutical announced on the evening of July 8. Recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-2173 injections and will conduct clinical trials in the near future. SHR-2173 injection is a therapeutic biological product independently developed by the company. It can exert anti-inflammatory and immune-suppressing biological effects by targeting abnormally activated immune cells. It is expected to reduce autoantibody levels, improve disease activity in patients with primary membranous nephropathy, and bring new treatment options to patients. Currently, there are no similar drugs on the market or in the clinical development stage at home or abroad. The company announced on the same day that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-9821 inhalation powder and will conduct clinical trials in the near future. HRS-9821 is a small molecule PDE3/PDE4 inhibitor that can effectively inhibit respiratory inflammation and bronchodilation. It is clinically intended for maintenance treatment of COPD.